The DOI matches its Crossref record; 133 of the 133 references it cites were found in a registry or an index.
The interaction of hepatic lipid and glucose metabolism in liver diseases
Open accessAbstract
It is widely known that the liver is a central organ in lipogenesis, gluconeogenesis and cholesterol metabolism. However, over the last decades, a variety of pathological conditions highlighted the importance of metabolic functions within the diseased liver. As observed in Western societies, an increase in the prevalence of obesity and the metabolic syndrome promotes pathophysiological changes that cause non-alcoholic fatty liver disease (NAFLD). NAFLD increases the susceptibility of the liver to acute liver injury and may lead to cirrhosis and hepatocellular cancer. Alterations in insulin response, β-oxidation, lipid storage and transport, autophagy and an imbalance in chemokines and nuclear receptor signaling are held accountable for these changes. Furthermore, recent studies revealed a role for lipid accumulation in inflammation and ER stress in the clinical context of liver regeneration and hepatic carcinogenesis. This review focuses on novel findings related to nuclear receptor signaling - including the vitamin D receptor and the liver receptor homolog 1 - in hepatic lipid and glucose uptake, storage and metabolism in the clinical context of NAFLD, liver regeneration, and cancer.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Inflammation and metabolic disorders
Hotamisligil, G. S. (2006) · Nature · doi:10.1038/nature05485 · Cited by 9,199 · cited 2×
“Obesity increases the TNFa production in adipocytes, which facilitates adipocyte IR and increases lipolysis rate [82].”
BackgroundOverweight, obesity, and mortality from cancer in a prospectively studied cohort of U.S. Adults
Calle, E. E., Rodriguez, C., Walker-Thurmond, K., & Thun, M. J. (2003) · New England Journal of Medicine · doi:10.1056/nejmoa021423 · Cited by 7,696 · cited 1×
“3A) [118,119].”
(1978) · Biochemical Education · doi:10.1016/0307-4412(78)90049-3 · Cited by 5,046
Autophagy regulates lipid metabolism
Singh, R., Kaushik, S., Wang, Y., Xiang, Y., Novak, I., Komatsu, M., Tanaka, K., Cuervo, A. M., & Czaja, M. J. (2009) · Nature · doi:10.1038/nature07976 · Cited by 3,975
Prevalence of Hepatic Steatosis in An Urban Population in the United States: Impact of Ethnicity
Browning, J. D., Szczepaniak, L. S., Dobbins, R., Nuremberg, P., Horton, J. D., Cohen, J. C., Grundy, S. M., & Hobbs, H. H. (2004) · Hepatology · doi:10.1002/hep.20466 · Cited by 3,664
Donnelly, K. L., Smith, C. I., Schwarzenberg, S. J., Jessurun, J., Boldt, M. D., & Parks, E. J. (2005) · Journal of Clinical Investigation · doi:10.1172/jci23621 · Cited by 3,604
The Natural History of Nonalcoholic Fatty Liver Disease: A Population-Based Cohort Study
Adams, L. A., Lymp, J. F., St. Sauver, J., Sanderson, S. O., Lindor, K. D., Feldstein, A., & Angulo, P. (2005) · Gastroenterology · doi:10.1053/j.gastro.2005.04.014 · Cited by 2,890
Endoplasmic reticulum stress and the inflammatory basis of metabolic disease
Hotamisligil, G. S. (2010) · Cell · doi:10.1016/j.cell.2010.02.034 · Cited by 2,802
Self-citationPromotion of tumorigenesis by heterozygous disruption of the beclin 1 autophagy gene
Qu, X., Yu, J., Bhagat, G., Furuya, N., Hibshoosh, H., Troxel, A., Rosen, J., Eskelinen, E.-L., Mizushima, N., Ohsumi, Y., et al. (2003) · Journal of Clinical Investigation · doi:10.1172/jci20039 · Cited by 2,311
Jung, C. H., Ro, S.-H., Cao, J., Otto, N. M., & Kim, D.-H. (2010) · FEBS Letters · doi:10.1016/j.febslet.2010.01.017 · Cited by 2,090
Cited by
Molecular mechanisms of hepatic lipid accumulation in non-alcoholic fatty liver disease
Ipsen, D. H., Lykkesfeldt, J., & Tveden-Nyborg, P. (2018) · Cellular and Molecular Life Sciences · doi:10.1007/s00018-018-2860-6 · Cited by 1,471
Trefts, E., Gannon, M., & Wasserman, D. H. (2017) · Current Biology · doi:10.1016/j.cub.2017.09.019 · Cited by 1,452
Lipidomics for studying metabolism
Han, X. (2016) · Nature Reviews Endocrinology · doi:10.1038/nrendo.2016.98 · Cited by 718
From NAFLD to NASH to cirrhosis—new insights into disease mechanisms
Wree, A., Broderick, L., Canbay, A., Hoffman, H. M., & Feldstein, A. E. (2013) · Nature Reviews Gastroenterology & Hepatology · doi:10.1038/nrgastro.2013.149 · Cited by 609
Self-citationNon-alcoholic fatty liver disease and obesity: Biochemical, metabolic and clinical presentations
Milić, S. (2014) · World Journal of Gastroenterology · doi:10.3748/wjg.v20.i28.9330 · Cited by 583
Bile acid receptors FXR and TGR5 signaling in fatty liver diseases and therapy
Chiang, J. Y. L., & Ferrell, J. M. (2020) · American Journal of Physiology-Gastrointestinal and Liver Physiology · doi:10.1152/ajpgi.00223.2019 · Cited by 580
The Subtle Balance between Lipolysis and Lipogenesis: A Critical Point in Metabolic Homeostasis
Saponaro, C., Gaggini, M., Carli, F., & Gastaldelli, A. (2015) · Nutrients · doi:10.3390/nu7115475 · Cited by 529
NLRP3 inflammasome activation is required for fibrosis development in NAFLD
Wree, A., McGeough, M. D., Peña, C. A., Schlattjan, M., Li, H., Inzaugarat, M. E., Messer, K., Canbay, A., Hoffman, H. M., & Feldstein, A. E. (2014) · Journal of Molecular Medicine · doi:10.1007/s00109-014-1170-1 · Cited by 486
“” These hits are characterized by the occurrence of parallel events that involve a complex interaction and cross talk between environmental factors and host genetics [8, 9].”
Self-citationNew insights into the pathophysiology of dyslipidemia in type 2 diabetes
Taskinen, M.-R., & Borén, J. (2015) · Atherosclerosis · doi:10.1016/j.atherosclerosis.2015.01.039 · Cited by 440
Krämer, J., Kang, R., Grimm, L. M., De Cola, L., Picchetti, P., & Biedermann, F. (2022) · Chemical Reviews · doi:10.1021/acs.chemrev.1c00746 · Cited by 449
Molecular pathways in non-alcoholic fatty liver disease
Auguet, T., Berlanga, A., Guiu-Jurado, E., & Porras, J. A. (2014) · Clinical and Experimental Gastroenterology · doi:10.2147/ceg.s62831 · Cited by 379
Rao, Y., Kuang, Z., Li, C., Guo, S., Xu, Y., Zhao, D., Hu, Y., Song, B., Jiang, Z., Ge, Z., et al. (2021) · Gut Microbes · doi:10.1080/19490976.2021.1927633 · Cited by 356
“The development of MAFLD involves multiple hits.59 Among them, hepatic steatosis is recognized as the initial factor, characterized by heavy lipid accumulation originated from increased de novo lipogenesis and/or excessive flux of exogenous FFAs.60 Hepatic lipogenesis is regulated by a series of lipogenic enzymes, inc…”
BackgroundNicotinamide Improves Aspects of Healthspan, but Not Lifespan, in Mice
Mitchell, S. J., Bernier, M., Aon, M. A., Cortassa, S., Kim, E. Y., Fang, E. F., Palacios, H. H., Ali, A., Navas-Enamorado, I., Di Francesco, A., et al. (2018) · Cell Metabolism · doi:10.1016/j.cmet.2018.02.001 · Cited by 338
The Hippo pathway in intestinal regeneration and disease
Hong, A. W., Meng, Z., & Guan, K.-L. (2016) · Nature Reviews Gastroenterology & Hepatology · doi:10.1038/nrgastro.2016.59 · Cited by 326
Hypoxia-inducible factors and the regulation of lipid metabolism
Mylonis, I., Simos, G., & Paraskeva, E. (2019) · Cells · doi:10.3390/cells8030214 · Cited by 316
PPAR-γ signaling in nonalcoholic fatty liver disease: Pathogenesis and therapeutic targets
Chen, H., Tan, H., Wan, J., Zeng, Y., Wang, J., Wang, H., & Lu, X. (2023) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2023.108391 · Cited by 311
Munukka, E., Rintala, A., Toivonen, R., Nylund, M., Yang, B., Takanen, A., Hänninen, A., Vuopio, J., Huovinen, P., Jalkanen, S., et al. (2017) · The ISME Journal · doi:10.1038/ismej.2017.24 · Cited by 278
Meta-analysis: vitamin D and non-alcoholic fatty liver disease
Eliades, M., Spyrou, E., Agrawal, N., Lazo, M., Brancati, F. L., Potter, J. J., Koteish, A. A., Clark, J. M., Guallar, E., & Hernaez, R. (2013) · Alimentary Pharmacology & Therapeutics · doi:10.1111/apt.12377 · Cited by 273
Athyros, V. G., Alexandrides, T. K., Bilianou, H., Cholongitas, E., Doumas, M., Ganotakis, E. S., Goudevenos, J., Elisaf, M. S., Germanidis, G., Giouleme, O., et al. (2017) · Metabolism · doi:10.1016/j.metabol.2017.02.014 · Cited by 219
The α-cell in diabetes mellitus
Gromada, J., Chabosseau, P., & Rutter, G. A. (2018) · Nature Reviews Endocrinology · doi:10.1038/s41574-018-0097-y · Cited by 143
Molecular mechanisms in liver repair and regeneration: from physiology to therapeutics
Ma, X., Huang, T., Chen, X., Li, Q., Liao, M., Fu, L., Huang, J., Yuan, K., Wang, Z., & Zeng, Y. (2025) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-024-02104-8 · Cited by 133
Altered Microbiota Diversity and Bile Acid Signaling in Cirrhotic and Noncirrhotic NASH-HCC
Sydor, S., Best, J., Messerschmidt, I., Manka, P., Vilchez-Vargas, R., Brodesser, S., Lucas, C., Wegehaupt, A., Wenning, C., Aßmuth, S., et al. (2020) · Clinical and Translational Gastroenterology · doi:10.14309/ctg.0000000000000131 · Cited by 127
Self-citationRole of bile acids in inflammatory liver diseases
Evangelakos, I., Heeren, J., Verkade, E., & Kuipers, F. (2021) · Seminars in Immunopathology · doi:10.1007/s00281-021-00869-6 · Cited by 121
Singh, A. K., Chaube, B., Zhang, X., Sun, J., Citrin, K. M., Canfrán-Duque, A., Aryal, B., Rotllan, N., Varela, L., Lee, R. G., et al. (2021) · Journal of Clinical Investigation · doi:10.1172/jci140989 · Cited by 115
Shi, C.-X., Zhao, M.-X., Shu, X.-D., Xiong, X.-Q., Wang, J.-J., Gao, X.-Y., Chen, Q., Li, Y.-H., Kang, Y.-M., & Zhu, G.-Q. (2016) · Scientific Reports · doi:10.1038/srep21924 · Cited by 108
GLP-1 Receptor Agonist and Non-Alcoholic Fatty Liver Disease
Lee, J., Hong, S.-W., Rhee, E.-J., & Lee, W.-Y. (2012) · Diabetes & Metabolism Journal · doi:10.4093/dmj.2012.36.4.262 · Cited by 87
Nuclear receptors as therapeutic targets in liver disease: are we there yet?
Rudraiah, S., Zhang, X., & Wang, L. (2016) · Annual Review of Pharmacology and Toxicology · doi:10.1146/annurev-pharmtox-010715-103209 · Cited by 87
“FOXO1 is directly and indirectly activated by PGC1α, HNF4α, ChREBP, and PPARα, and furthermore, PGC1α-FOXO1 complex is considered a potential target for antigluconeogenic therapies for diabetes mellitus (12, 22).”
InfluentialSo, W. Y., & Leung, P. S. (2016) · The International Journal of Biochemistry & Cell Biology · doi:10.1016/j.biocel.2016.07.022 · Cited by 83
NeuCode Proteomics Reveals Bap1 Regulation of Metabolism
Baughman, J. M., Rose, C. M., Kolumam, G., Webster, J. D., Wilkerson, E. M., Merrill, A. E., Rhoads, T. W., Noubade, R., Katavolos, P., Lesch, J., et al. (2016) · Cell Reports · doi:10.1016/j.celrep.2016.05.096 · Cited by 73
Engineering Liver Microtissues for Disease Modeling and Regenerative Medicine
Huang, D. (., Gibeley, S. B., Xu, C., Xiao, Y., Celik, O., Ginsberg, H. N., & Leong, K. W. (2020) · Advanced Functional Materials · doi:10.1002/adfm.201909553 · Cited by 65
Seth, R. K., Kimono, D., Alhasson, F., Sarkar, S., Albadrani, M., Lasley, S. K., Horner, R., Janulewicz, P., Nagarkatti, M., Nagarkatti, P., et al. (2018) · Toxicology and Applied Pharmacology · doi:10.1016/j.taap.2018.05.006 · Cited by 55
“The liver is the principal organ for gluconeogenesis, lipogenesis and cholesterol metabolism (Bechmann et al., 2012).”
Insulin Signaling as a Potential Natural Killer Cell Checkpoint in Fatty Liver Disease
Amer, J., Salhab, A., Noureddin, M., Doron, S., Abu‐Tair, L., Ghantous, R., Mahamid, M., & Safadi, R. (2018) · Hepatology Communications · doi:10.1002/hep4.1146 · Cited by 42
Fang, W., Deng, Z., Benadjaoud, F., Yang, C., & Shi, G.-P. (2020) · Translational Research · doi:10.1016/j.trsl.2020.04.011 · Cited by 40
Alves Costa Silva, C., Piccinno, G., Suissa, D., Bourgin, M., Schreibelt, G., Durand, S., Birebent, R., Fidelle, M., Sow, C., Aprahamian, F., et al. (2024) · Nature Communications · doi:10.1038/s41467-024-45357-1 · Cited by 33
“In addition to absorbing circulating FA, hepatocytes synthesize FA from dietary carbohydrates that reach the hepatocytes via the portal vein 72 .”
Rusu, I., Pirlog, R., Chiroi, P., Nutu, A., Puia, V. R., Fetti, A. C., Rusu, D. R., Berindan-Neagoe, I., & Al Hajjar, N. (2022) · International Journal of Molecular Sciences · doi:10.3390/ijms232012370 · Cited by 27
Physiological and pathophysiological actions of insulin in the liver
Kubota, N., Kubota, T., & Kadowaki, T. (2025) · Endocrine Journal · doi:10.1507/endocrj.ej24-0192 · Cited by 19
Fasting‐sensitive SUMO‐switch on Prox1 controls hepatic cholesterol metabolism
Alfaro, A. J., Dittner, C., Becker, J., Loft, A., Mhamane, A., Maida, A., Georgiadi, A., Tsokanos, F., Klepac, K., Molocea, C., et al. (2023) · The EMBO Reports · doi:10.15252/embr.202255981 · Cited by 14
Sun, Y., Yin, S., Cui, J., Wang, Z., Han, Y., Ma, D., Wang, S., Wu, J., Cao, Y., Jiang, C., et al. (2024) · Nano Research · doi:10.1007/s12274-023-5940-3 · Cited by 13
Single MHC‐I Expression Promotes Virus‐Induced Liver Immunopathology
Xu, H. C., Huang, J., Pandyra, A. A., Pandey, P., Wang, R., Zhang, Z., Zhuang, Y., Gertzen, C. G. W., Münk, C., Herebian, D., et al. (2022) · Hepatology Communications · doi:10.1002/hep4.1913 · Cited by 9
Metadata
- Authors
- Bechmann, L. P., Hannivoort, R. A., Gerken, G., Hotamisligil, G. S., Trauner, M., & Canbay, A.
- Venue
- Journal of Hepatology
- Publisher
- Elsevier BV
- Published
- 2012-04
- Volume
- 56
- Issue
- 4
- Pages
- 952-964
- ISSN
- 0168-8278 (ISSN-L)
- OpenAlex
- W2095591310
- Cited by
- 994
- References
- 133
- FWCI
- 18.80
- Type
- journal article
- Language
- en
- Open access
- hybrid
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.